|
|
||||||||
THE ROLE OF CONJUGATED LINOLEIC ACID IN HUMAN HEALTH |
1 From the Department of Human Nutritional Sciences (HW, SA, SF-W, RM, HA, and MO) and the Department Pediatrics and Child Health (HW, EN, NB-C, HA, and MO), University of Manitoba, Winnipeg, Manitoba, Canada
ABSTRACT
Background: Feeding conjugated linoleic acid (CLA) is reported to reduce prostaglandin E2 synthesis, which is required for parathyroid hormone (PTH) release.
Objective: This study was undertaken to determine whether CLA would suppress hyperparathyroidism and the resulting high-turnover bone disease in a rat model of polycystic kidney disease (PKD).
Design: Outcome measurements were conducted after 8 wk of feeding diets supplemented with and without CLA (1% of dietary fat) to Han:SPRD-cy male rats (n = 52). PTH, bone formation, and resorption were assessed in addition to femur bone mass with use of dual-energy X-ray absorptiometry.
Results: CLA feeding resulted in attenuation of PTH concentrations in both PKD-affected and nonaffected rats (by 60%) but did not significantly alter bone formation and resorption.
Conclusion: Reduction in PTH may open possibilities for CLA as an adjunctive therapy in secondary hyperparathyroidism.
Key Words: Polycystic kidney disease bone metabolism parathyroid hormone conjugated linoleic acid Han:SPRD-cy rats
This article has been cited by other articles:
![]() |
I. Platt, L. G. Rao, and A. El-Sohemy Isomer-Specific Effects of Conjugated Linoleic Acid on Mineralized Bone Nodule Formation from Human Osteoblast-LikeCells Exp Biol Med, February 1, 2007; 232(2): 246 - 252. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |